BioCardia, Inc. (NASDAQ:BCDA) Sees Large Decrease in Short Interest

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 23,700 shares, a decrease of 57.8% from the February 13th total of 56,200 shares. Based on an average daily trading volume, of 51,200 shares, the short-interest ratio is currently 0.5 days. Currently, 0.7% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Alliance Global Partners upgraded BioCardia from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of BioCardia in a research report on Wednesday, December 18th.

BioCardia Stock Up 0.8 %

Shares of BioCardia stock opened at $2.57 on Friday. BioCardia has a 52-week low of $1.63 and a 52-week high of $6.41. The company has a market capitalization of $11.78 million, a P/E ratio of -0.61 and a beta of 1.28. The company has a 50 day moving average of $2.37 and a 200 day moving average of $2.42.

Insider Buying and Selling

In other BioCardia news, Director Simon H. Stertzer purchased 22,753 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was acquired at an average price of $2.30 per share, for a total transaction of $52,331.90. Following the completion of the purchase, the director now directly owns 40,602 shares in the company, valued at approximately $93,384.60. The trade was a 127.47 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired a total of 26,353 shares of company stock valued at $60,585 in the last ninety days. Company insiders own 20.00% of the company’s stock.

Institutional Investors Weigh In On BioCardia

An institutional investor recently bought a new position in BioCardia stock. CM Management LLC bought a new stake in BioCardia, Inc. (NASDAQ:BCDA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $54,000. CM Management LLC owned about 0.55% of BioCardia at the end of the most recent reporting period. Hedge funds and other institutional investors own 20.57% of the company’s stock.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.